Contamination Control & Annex 1

The Contamination Control Strategy (CCS)

The headline change in the 2022 Annex 1 is the requirement for a documented Contamination Control Strategy: a site-wide description of the critical control points and an assessment of the effectiveness of all the controls — design, procedural, technical, and organisational — used to manage contamination risk. The CCS is not a single document to file and forget; it is a living evaluation that shows the controls work together, not just individually.

The CCS forces a shift from a list of compliant elements to a coherent argument. It asks: given this facility, these processes, and these people, where can contamination enter, what stops it, and how do we know the sum of those controls is adequate? Quality Risk Management is the engine that drives it.

Cleanroom classification and environmental monitoring

Cleanrooms are classified by airborne particle concentration — Grade A/B/C/D in EU GMP, aligned with the ISO 14644-1 classes — both at rest and in operation. ISO 14644-2 governs how that classification is monitored over time. Grade A (the critical zone for aseptic processing) demands the tightest limits and, under Annex 1, continuous monitoring of the critical zone.

Classification is a design and qualification activity; environmental monitoring is the ongoing evidence that the controlled state holds during real production. A monitoring programme is built on a risk-based rationale for locations, frequencies, and alert/action limits — not on a generic template — and its results feed straight back into the CCS.

Sterility assurance: barriers, people, and process

Annex 1 pushes hard toward engineered barrier technology — isolators and RABS (restricted-access barrier systems) — to separate the operator, the largest source of contamination, from the critical zone. Where aseptic processing still relies on people, gowning qualification, aseptic technique, and aseptic process simulation (media fills) carry the assurance.

The FDA’s 2004 aseptic-processing guidance covers the same ground from the US perspective and remains a foundational reference: cleanroom design, personnel, environmental monitoring, and media fills. The two documents are read together by any manufacturer supplying both markets.

Why it is the highest-stakes discipline

A contamination failure in a sterile product is a direct patient-harm event, which is why aseptic and sterile manufacturing draws the most intense inspection scrutiny of any GxP area. Annex 1 findings — inadequate CCS, weak monitoring rationale, poor aseptic behaviour — are among the most common and most serious cited in sterile-product inspections.